Granules India Share Price
Sector: Biotechnology & Drugs
496.80 -0.35 (-0.07%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
495.50
Today’s High
503.05
52 Week Low
412.05
52 Week High
724.55
497.20 +0.30 (0.06%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
495.00
Today’s High
503.15
52 Week Low
422.00
52 Week High
721.00
Key Metrics
- Market Cap (In Cr) 12033.96
- Beta 0.65
- Div. Yield (%) 0.3
- P/B 3.25
- TTM P/E 23.51
- Sector P/E 22.43
- D/E 0
- Open Price 500
- Prev Close 497.15
Granules India Analysis
Price Analysis
-
1 Week2.02%
-
3 Months2.23%
-
6 Month-15.13%
-
YTD-16.06%
-
1 Year-0.29%
Risk Meter
- 40% Low risk
- 40% Moderate risk
- 40% Balanced Risk
- 40% High risk
- 40% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 2
- 2
- 2
- 2
- Buy
- 2
- 2
- 2
- 2
- Hold
- 0.00
- 0.00
- 0.00
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 4
- 4
- 4
- 4
Granules India News
Four Indian pharma stocks that may be hit by US pharma tariff threat
6 min read . 21 Jun 2025Gland Pharma, Cipla among 8 stocks that jumped up to 28% since April
3 min read . 06 Jun 2025Q4 results today: IRCTC, Deepak Nitrate, SAIL, Cummins, Bata India on May 28
2 min read . 28 May 2025Granules India Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 4481.61
- Selling/ General/ Admin Expenses Total
- 659.8
- Depreciation/ Amortization
- 225.5
- Other Operating Expenses Total
- 1150.87
- Total Operating Expense
- 3731.12
- Operating Income
- 750.49
- Net Income Before Taxes
- 660.17
- Net Income
- 501.52
- Diluted Normalized EPS
- 19.72
- Period
- 2025
- Total Assets
- 6252.56
- Total Liabilities
- 2536.98
- Total Equity
- 3715.58
- Tangible Book Valueper Share Common Eq
- 144.44
- Period
- 2025
- Cashfrom Operating Activities
- 866.57
- Cashfrom Investing Activities
- -691.29
- Cashfrom Financing Activities
- -92.51
- Net Changein Cash
- 85.01
- Period
- 2024
- Total Revenue
- 4506.37
- Selling/ General/ Admin Expenses Total
- 1221.32
- Depreciation/ Amortization
- 207.33
- Other Operating Expenses Total
- 27.12
- Total Operating Expense
- 3853.54
- Operating Income
- 652.83
- Net Income Before Taxes
- 547.23
- Net Income
- 405.31
- Diluted Normalized EPS
- 16.8
- Period
- 2024
- Total Assets
- 5520.98
- Total Liabilities
- 2295.44
- Total Equity
- 3225.54
- Tangible Book Valueper Share Common Eq
- 122.7
- Period
- 2024
- Cashfrom Operating Activities
- 439.41
- Cashfrom Investing Activities
- -360.16
- Cashfrom Financing Activities
- 7.66
- Net Changein Cash
- 89.54
- Period
- 2023
- Total Revenue
- 4511.92
- Selling/ General/ Admin Expenses Total
- 1121.77
- Depreciation/ Amortization
- 184.49
- Other Operating Expenses Total
- 12.45
- Total Operating Expense
- 3774.27
- Operating Income
- 737.64
- Net Income Before Taxes
- 687.17
- Net Income
- 516.6
- Diluted Normalized EPS
- 21.06
- Period
- 2023
- Total Assets
- 4904.56
- Total Liabilities
- 2069.65
- Total Equity
- 2834.91
- Tangible Book Valueper Share Common Eq
- 105.11
- Period
- 2023
- Cashfrom Operating Activities
- 738.75
- Cashfrom Investing Activities
- -191.36
- Cashfrom Financing Activities
- -440.29
- Net Changein Cash
- 106.84
- Period
- 2022
- Total Revenue
- 3764.92
- Selling/ General/ Admin Expenses Total
- 1006.92
- Depreciation/ Amortization
- 158.63
- Other Operating Expenses Total
- 14.58
- Total Operating Expense
- 3190.03
- Operating Income
- 574.89
- Net Income Before Taxes
- 558
- Net Income
- 412.76
- Diluted Normalized EPS
- 16.74
- Period
- 2022
- Total Assets
- 4512.9
- Total Liabilities
- 1926.36
- Total Equity
- 2586.53
- Tangible Book Valueper Share Common Eq
- 92.13
- Period
- 2022
- Cashfrom Operating Activities
- 332.05
- Cashfrom Investing Activities
- -380.11
- Cashfrom Financing Activities
- 190
- Net Changein Cash
- 142.88
- Period
- 2021
- Total Revenue
- 3237.54
- Selling/ General/ Admin Expenses Total
- 861.97
- Depreciation/ Amortization
- 151.46
- Other Operating Expenses Total
- 9.79
- Total Operating Expense
- 2525.18
- Operating Income
- 712.36
- Net Income Before Taxes
- 704.36
- Net Income
- 549.46
- Diluted Normalized EPS
- 21.99
- Period
- 2021
- Total Assets
- 3713.45
- Total Liabilities
- 1540.18
- Total Equity
- 2173.27
- Tangible Book Valueper Share Common Eq
- 75.03
- Period
- 2021
- Cashfrom Operating Activities
- 432.48
- Cashfrom Investing Activities
- -277.14
- Cashfrom Financing Activities
- -299.31
- Net Changein Cash
- -144.09
- Period
- 2020
- Total Revenue
- 2598.65
- Selling/ General/ Admin Expenses Total
- 671.29
- Depreciation/ Amortization
- 136.95
- Other Operating Expenses Total
- 6.68
- Total Operating Expense
- 2182.3
- Operating Income
- 416.35
- Net Income Before Taxes
- 451.13
- Net Income
- 335.4
- Diluted Normalized EPS
- 12.56
- Period
- 2020
- Total Assets
- 3228.36
- Total Liabilities
- 1384.63
- Total Equity
- 1843.72
- Tangible Book Valueper Share Common Eq
- 58.3
- Period
- 2020
- Cashfrom Operating Activities
- 476.19
- Cashfrom Investing Activities
- -160.63
- Cashfrom Financing Activities
- -212.86
- Net Changein Cash
- 102.9
- Period
- 2019
- Total Revenue
- 2279.2
- Selling/ General/ Admin Expenses Total
- 556.57
- Depreciation/ Amortization
- 105.48
- Other Operating Expenses Total
- 7.23
- Total Operating Expense
- 2000.28
- Operating Income
- 278.92
- Net Income Before Taxes
- 325.52
- Net Income
- 236.41
- Diluted Normalized EPS
- 9.29
- Period
- 2019
- Total Assets
- 2982.81
- Total Liabilities
- 1453.34
- Total Equity
- 1529.47
- Tangible Book Valueper Share Common Eq
- 45.64
- Period
- 2019
- Cashfrom Operating Activities
- 262.24
- Cashfrom Investing Activities
- -269.82
- Cashfrom Financing Activities
- -17.43
- Net Changein Cash
- -25.01
- Period
- 2025-03-31
- Total Revenue
- 1197.43
- Selling/ General/ Admin Expenses Total
- 169.12
- Depreciation/ Amortization
- 63.5
- Other Operating Expenses Total
- 337.58
- Total Operating Expense
- 977.82
- Operating Income
- 219.61
- Net Income Before Taxes
- 197.55
- Net Income
- 152.03
- Diluted Normalized EPS
- 5.29
- Period
- 2025-03-31
- Total Assets
- 6252.56
- Total Liabilities
- 2536.98
- Total Equity
- 3715.58
- Tangible Book Valueper Share Common Eq
- 144.44
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 866.57
- Cashfrom Investing Activities
- -691.29
- Cashfrom Financing Activities
- -92.51
- Net Changein Cash
- 85.01
- Period
- 2024-12-31
- Total Revenue
- 1137.7
- Selling/ General/ Admin Expenses Total
- 167.64
- Depreciation/ Amortization
- 56.61
- Other Operating Expenses Total
- 304.09
- Total Operating Expense
- 964.01
- Operating Income
- 173.68
- Net Income Before Taxes
- 152.79
- Net Income
- 117.6
- Diluted Normalized EPS
- 4.85
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 966.62
- Selling/ General/ Admin Expenses Total
- 159.43
- Depreciation/ Amortization
- 52.52
- Other Operating Expenses Total
- 236.66
- Total Operating Expense
- 815.82
- Operating Income
- 150.8
- Net Income Before Taxes
- 128.38
- Net Income
- 97.23
- Diluted Normalized EPS
- 4.01
- Period
- 2024-09-30
- Total Assets
- 5432.7
- Total Liabilities
- 2005.47
- Total Equity
- 3427.24
- Tangible Book Valueper Share Common Eq
- 131.78
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 416.82
- Cashfrom Investing Activities
- -278.66
- Cashfrom Financing Activities
- -310.68
- Net Changein Cash
- -172.25
- Period
- 2024-06-30
- Total Revenue
- 1179.87
- Selling/ General/ Admin Expenses Total
- 163.61
- Depreciation/ Amortization
- 52.87
- Other Operating Expenses Total
- 272.55
- Total Operating Expense
- 973.47
- Operating Income
- 206.4
- Net Income Before Taxes
- 181.44
- Net Income
- 134.65
- Diluted Normalized EPS
- 5.55
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 1175.78
- Selling/ General/ Admin Expenses Total
- 151.69
- Depreciation/ Amortization
- 53.18
- Other Operating Expenses Total
- 298.77
- Total Operating Expense
- 973.25
- Operating Income
- 202.53
- Net Income Before Taxes
- 175.64
- Net Income
- 129.65
- Diluted Normalized EPS
- 5.34
- Period
- 2024-03-31
- Total Assets
- 5520.98
- Total Liabilities
- 2295.44
- Total Equity
- 3225.54
- Tangible Book Valueper Share Common Eq
- 122.7
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 439.41
- Cashfrom Investing Activities
- -360.16
- Cashfrom Financing Activities
- 7.66
- Net Changein Cash
- 89.54
- Period
- 2023-12-31
- Total Revenue
- 1155.58
- Selling/ General/ Admin Expenses Total
- 157.01
- Depreciation/ Amortization
- 52.39
- Other Operating Expenses Total
- 250.77
- Total Operating Expense
- 957.5
- Operating Income
- 198.09
- Net Income Before Taxes
- 170.1
- Net Income
- 125.65
- Diluted Normalized EPS
- 5.18
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Granules India Technical
Moving Average
SMA
- 5 Day489.62
- 10 Day498.98
- 20 Day515.66
- 50 Day494.7
- 100 Day506.64
- 300 Day544.07
Granules India Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Sanofi India
- 6180
- 4.95
- 0.08
- 7593.6
- 4145.9
- 14229.2
- Alivus Life Sciences
- 999.8
- 4.45
- 0.45
- 1335
- 820.05
- 12203.45
- Granules India
- 496.8
- -0.35
- -0.07
- 724.55
- 412.05
- 12033.96
- Marksans Pharma
- 253.15
- 6.05
- 2.45
- 358.5
- 158.25
- 11476.49
- Procter & Gamble Health
- 5905.15
- 28.85
- 0.49
- 6107.55
- 4912.3
- 9888.51
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Sanofi India
- 41.72
- 16.52
- 32.83
- 21.53
- Alivus Life Sciences
- 25.17
- 4.33
- 24.68
- 20.24
- Granules India
- 25.2
- 3.24
- 17.54
- 11.64
- Marksans Pharma
- 29.41
- 4.54
- 18.54
- 14.58
- Procter & Gamble Health
- 44.62
- 18.06
- -
- -
Granules India Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 28-May-25
- Audited Results & Final Dividend
- 24-Jan-25
- Quarterly Results
- 06-Nov-24
- Quarterly Results
- 30-Jul-24
- Quarterly Results
- 15-May-24
- Audited Results & Final Dividend
- 23-Jan-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 09-Aug-23
- Quarterly Results
- 16-May-23
- Audited Results & Final Dividend
- 24-Jan-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 06-Aug-24
- 15-May-24
- AGM
- 04-Apr-24
- 29-Feb-24
- POM
- 10-Aug-23
- 18-May-23
- AGM
- 25-Feb-22
- 24-Jan-22
- POM
- 05-Aug-21
- 11-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 28-May-25
- 31-Jul-25
- 31-Jul-25
- 1.5
- 15-May-24
- -
- 30-Jul-24
- 1.5
- 16-May-23
- 03-Aug-23
- 03-Aug-23
- 1.5
- 18-May-22
- -
- 19-Jul-22
- 0.75
- 08-Feb-22
- 18-Feb-22
- 17-Feb-22
- 0.25
- 12-Nov-21
- 25-Nov-21
- 24-Nov-21
- 0.25
- 27-Jul-21
- 06-Aug-21
- 05-Aug-21
- 0.25
- 11-May-21
- -
- 28-Jul-21
- 0.75
- 28-Jan-21
- 09-Feb-21
- 08-Feb-21
- 0.25


